PHARMACY POLICY STATEMENT
Indiana Medicaid

	Must use valid NDC code
BENEFIT TYPE	Medical
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Livtencity is a cytomegalovirus pUL97 kinsae inhibitor initially approved by the FDA in November 2021. It is the first medication for the treatment of refractory post-transplant CMV with or without genotypic resistance. Livtencity was evaluated in the SOLSTICE Phase 3 clinical trial, where 56% [95% CI 22·80–42·74]; p<0·001)] achieved CMV viremia clearance by the end of week 8. Livtencity is not FDA-approved in patients with human immunodeficiency virus (HIV) or other nontransplant populations, nor is it approved for prophylaxis of CMV infection.

Livtencity (maribar) will be considered for coverage when the following criteria are met:

Post-Transplant CMV Infection

For initial authorization:

1. Member is at least 12 years of age and weigh at least 35 kg; AND
2. Medication must be prescribed by or in consultation with an infectious disease specialist, hematologist, or transplant specialist; AND
3. Member has documentation of previous hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT); AND
4. Member has documentation of CMV infection, as evidenced by &09 '1$ RI • ,8 P/ LQ ZKR EORRG RU • ,8 P/ LQ SODVPD
5. Member has a previous 14 day trial and inadequate response to at least one of the following: ganciclovir, valganciclovir, cidofovir or foscarnet; AND
6. Member will not be using with ganciclovir or valganciclovir.
7. Dosage allowed/Quantity limit: 400mg twice daily (112 tablets per 28 days).

If

1. / L Y W H Q F L W \ P D U L E D Y L U > S U H V F U L E L Q J L Q I R U P D W L R Q @ / H [L Q J W R Q
2. Del Pozo Martín Y. 47th Annual Meeting of the EBMT. Lancet Haematol. 2021 May;8(5):e317-e318.
3. Razonable RR, et al. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512
4. Robin K et al, Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial. *Clinical Infectious Diseases*, 2021;ciab988, K W W S V J G R L R U G F L D E

Effective date:
Revised date: 01 07 2022